or Try an Advanced Search...

    Technical Analysis for ALLK - Allakos Inc.

    Grade Last Price % Change Price Change
    F 1.26 2.86% 0.04
    ALLK closed up 2.86 percent on Wednesday, May 8, 2024, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical ALLK trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Earnings Movers Other 0.00%
    Weak + Overbought Other 0.00%
    Above Upper BB Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Older End-of-Day Signals for ALLK ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 17 hours ago
    Up 5% about 17 hours ago
    Up 3% about 17 hours ago
    Gap Down Partially Closed about 18 hours ago
    Gap Down Closed about 18 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ALLK Chart by TradingView
    Basic chart:

    Profile

    Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biology Disease Immunology Immune System Antibodies Inflammation Antibody Cell Biology Allergy Allergic Conjunctivitis Mastocytosis Systemic Mastocytosis Mast Cell Eosinophil

    Is ALLK a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 16 Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4
    Mar 14 Allakos GAAP EPS of -$0.71 misses by $0.20
    Mar 14 Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    Feb 26 Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
    Jan 18 Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
    Jan 18 Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks
    Jan 17 Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
    Jan 17 Allakos extends losses as analysts downgrade on Phase 2 setback
    Jan 17 ELAB, KIND and RLX among pre-market losers
    Jan 17 Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
    See more ALLK news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.64
    52 Week Low 0.9799
    Average Volume 517,556
    200-Day Moving Average 2.16
    50-Day Moving Average 1.23
    20-Day Moving Average 1.10
    10-Day Moving Average 1.12
    Average True Range 0.09
    RSI (14) 59.84
    ADX 19.75
    +DI 24.77
    -DI 12.07
    Chandelier Exit (Long, 3 ATRs) 1.02
    Chandelier Exit (Short, 3 ATRs) 1.26
    Upper Bollinger Bands 1.24
    Lower Bollinger Band 0.96
    Percent B (%b) 1.07
    BandWidth 25.37
    MACD Line -0.01
    MACD Signal Line -0.04
    MACD Histogram 0.0318
    Fundamentals Value
    Market Cap 110.22 Million
    Num Shares 87.5 Million
    EPS -1.53
    Price-to-Earnings (P/E) Ratio -0.82
    Price-to-Sales 0.00
    Price-to-Book 0.53
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.44
    Resistance 3 (R3) 1.43 1.37 1.41
    Resistance 2 (R2) 1.37 1.32 1.37 1.40
    Resistance 1 (R1) 1.31 1.29 1.34 1.32 1.39
    Pivot Point 1.25 1.25 1.26 1.25 1.25
    Support 1 (S1) 1.19 1.20 1.22 1.20 1.13
    Support 2 (S2) 1.13 1.17 1.13 1.12
    Support 3 (S3) 1.07 1.13 1.11
    Support 4 (S4) 1.08